US Broker Ratings

Progyny, Inc. (PGNY) Stock Analysis: Investor Outlook with a Promising 10% Upside

Progyny, Inc. (NASDAQ: PGNY) is capturing the attention of investors with a unique position in the healthcare sector, specifically within the healthcare plans industry. Known for its innovative approach to..

Healthcare Services Group, Inc. (HCSG) Stock Analysis: 19% Potential Upside and Strong Revenue Growth

Healthcare Services Group, Inc. (NASDAQ: HCSG) stands out in the healthcare sector, specifically within the medical care facilities industry. With a market capitalization of $1.31 billion, the company focuses on..

Integra LifeSciences Holdings C (IART) Stock Analysis: Navigating a 23.41% Potential Upside Amidst Challenges

Integra LifeSciences Holdings C (NASDAQ: IART), a pivotal player in the healthcare sector, is garnering attention with its significant potential upside of 23.41% based on current analyst ratings. With a..

Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis: Riding the Biotech Wave with 8.93% Potential Upside

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH), a Canadian biopharmaceutical company, has been making waves in the healthcare sector, particularly within the biotechnology industry. With a market capitalization of $2.02 billion, the..

Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis: Exploring an 18.69% Upside Potential

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) presents a compelling case for investors seeking opportunities in the healthcare sector, particularly within the specialty and generic drug manufacturing industry. With a market capitalization..

Brookdale Senior Living Inc. (BKD) Stock Analysis: Navigating Healthcare Sector Growth with a 6.67% Upside

Brookdale Senior Living Inc. (NYSE: BKD) stands as a significant player in the healthcare sector, specifically within the medical care facilities industry. With a market capitalization of $2.58 billion, this..

Pulse Biosciences, Inc (PLSE) Stock Analysis: Exploring a 50.68% Potential Upside in the Healthcare Sector

Pulse Biosciences, Inc (NASDAQ: PLSE) is making waves in the healthcare sector as a cutting-edge bioelectric medicine company. Specializing in advanced medical instruments and supplies, Pulse Biosciences stands out with..

Omnicell, Inc. (OMCL) Stock Analysis: Exploring a 9.74% Potential Upside in Healthcare Tech

Omnicell, Inc. (NASDAQ: OMCL), a prominent player in the health information services industry, is capturing the attention of investors seeking opportunities in the healthcare sector. With a market cap of..

Tandem Diabetes Care, Inc. (TNDM) Stock Analysis: Navigating Growth with a 7% Upside Potential

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a pivotal player in the healthcare sector, specifically within the medical devices industry, is drawing significant attention from investors. With a current market capitalization..

Belite Bio, Inc (BLTE) Stock Analysis: Unveiling a 15.63% Upside in Innovative Biotechnology Ventures

Belite Bio, Inc (NASDAQ: BLTE) stands at the forefront of the biotech sector with its innovative approach to tackling unmet medical needs in retinal degenerative eye diseases. With a market..

Astrana Health Inc. (ASTH) Stock Analysis: A Promising 37.47% Potential Upside Awaits Investors

Astrana Health Inc. (NASDAQ: ASTH), a notable player in the healthcare sector, has caught the attention of investors with its robust revenue growth and significant potential upside. Headquartered in Alhambra,..

Kymera Therapeutics, Inc. (KYMR) Stock Analysis: A Biotech Leader with a 59.70% Potential Upside

Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a compelling player in the biotechnology sector, offering investors a unique opportunity to tap into the cutting-edge field of targeted protein degradation. As a..

The Pennant Group, Inc. (PNTG) Investor Outlook: Exploring a 27.93% Upside Potential

For investors with an eye on the healthcare sector, The Pennant Group, Inc. (NASDAQ: PNTG) presents an intriguing opportunity. As a prominent player in the medical care facilities industry, this..

Agios Pharmaceuticals, Inc. (AGIO): Investor Outlook Highlights a Potential 33% Upside

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is capturing investor attention with its promising potential upside of 33.42%, making it a compelling consideration for those interested in the biotechnology sector. With a..

Vera Therapeutics, Inc. (VERA) Stock Analysis: A Biotech Gem with a 59.66% Potential Upside

Vera Therapeutics, Inc. (VERA) is drawing significant attention in the biotechnology sector, thanks to its promising pipeline of innovative treatments targeting serious immunological diseases. With a market capitalization of $3.34..

ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis: A Promising Biotech with 14.92% Upside Potential

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a key player in the biotechnology sector, has caught the attention of investors with its focus on treatments for central nervous system disorders and rare..

MiMedx Group, Inc (MDXG) Stock Analysis: Exploring a Potential 92.73% Upside with Strong Buy Ratings

MiMedx Group, Inc. (NASDAQ: MDXG) is gaining attention in the biotechnology sector, a promising domain within healthcare, particularly for investors seeking growth potential. With a market capitalization of $937.49 million,..

NovoCure Limited (NVCR) Stock Analysis: Unpacking the 77.92% Potential Upside

NovoCure Limited (NASDAQ: NVCR), a prominent player in the healthcare sector, specifically in medical devices, is drawing significant attention from investors due to its innovative approach in treating solid tumor..

U.S. Physical Therapy, Inc. (USPH) Stock Analysis: Exploring a 25% Upside Potential

U.S. Physical Therapy, Inc. (NYSE: USPH) is a prominent player in the healthcare sector, specifically within the medical care facilities industry. With a market capitalization of $1.28 billion, the company..

Structure Therapeutics Inc. (GPCR) Stock Analysis: Navigating a 62.5% Potential Upside in the Biotech Sector

Structure Therapeutics Inc. (NASDAQ: GPCR) is making waves in the healthcare sector, particularly within the biotechnology industry, as a clinical-stage biopharmaceutical company. With a market capitalization of $4.43 billion, Structure..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds